The combined effect of total body irradiation (TBI) and cyclosporin a (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation

A. Bacigalupo, V. Vitale, R. Corvö, S. Barra, T. Lamparelli, F. Gualandi, N. Mordini, G. Berisso, S. Bregante, A. M. Raiola, M. T. Van Lint, F. Frassoni

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

One hundred and fifty acute myeloid leukaemia (AML) patients in first remission received an allogeneic bone marrow transplant (BMT), after conditioning with cyclophosphamide 120 mg/kg and total body irradiation (TBI) 3.3 Gy x 3 (total nominal dose 9.9). The received dose, as recorded by thermoluminescent dosimeters, ranged between 7.83 and 12.25 Gy. Patients who received TBI <9.9 Gy (n=34) had a significantly higher relapse rate when compared with patients receiving ≥9.9 Gy (n=116) (43% vs. 19%; P=0.002). Graft versus host disease (GvHD) prophylaxis consisted of cyclosporin A (CyA) with or without methotrexate (MTX). The dose of CyA was either 1 or 5 mg/kg/day i.v. from day -1 to + 20, then 10 mg/kg/day orally until day + 365. Patients receiving 5 mg/kg CyA (n=40) had a higher risk of relapse (49% vs. 15%; P=0.0001). Thus, low-dose TBI (

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalBritish Journal of Haematology
Volume108
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Whole-Body Irradiation
Homologous Transplantation
Bone Marrow Transplantation
Acute Myeloid Leukemia
Cyclosporine
Recurrence
Graft vs Host Disease
Methotrexate
Cyclophosphamide
Bone Marrow
Transplants

Keywords

  • Acute myeloid leukaemia
  • Cyclosporin
  • Graft vs. leukaemia
  • Total body irradiation

ASJC Scopus subject areas

  • Hematology

Cite this

@article{9faee5502e954e7c84d9c4eb5915e76f,
title = "The combined effect of total body irradiation (TBI) and cyclosporin a (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation",
abstract = "One hundred and fifty acute myeloid leukaemia (AML) patients in first remission received an allogeneic bone marrow transplant (BMT), after conditioning with cyclophosphamide 120 mg/kg and total body irradiation (TBI) 3.3 Gy x 3 (total nominal dose 9.9). The received dose, as recorded by thermoluminescent dosimeters, ranged between 7.83 and 12.25 Gy. Patients who received TBI <9.9 Gy (n=34) had a significantly higher relapse rate when compared with patients receiving ≥9.9 Gy (n=116) (43{\%} vs. 19{\%}; P=0.002). Graft versus host disease (GvHD) prophylaxis consisted of cyclosporin A (CyA) with or without methotrexate (MTX). The dose of CyA was either 1 or 5 mg/kg/day i.v. from day -1 to + 20, then 10 mg/kg/day orally until day + 365. Patients receiving 5 mg/kg CyA (n=40) had a higher risk of relapse (49{\%} vs. 15{\%}; P=0.0001). Thus, low-dose TBI (",
keywords = "Acute myeloid leukaemia, Cyclosporin, Graft vs. leukaemia, Total body irradiation",
author = "A. Bacigalupo and V. Vitale and R. Corv{\"o} and S. Barra and T. Lamparelli and F. Gualandi and N. Mordini and G. Berisso and S. Bregante and Raiola, {A. M.} and {Van Lint}, {M. T.} and F. Frassoni",
year = "2000",
doi = "10.1046/j.1365-2141.2000.01809.x",
language = "English",
volume = "108",
pages = "99--104",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - The combined effect of total body irradiation (TBI) and cyclosporin a (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation

AU - Bacigalupo, A.

AU - Vitale, V.

AU - Corvö, R.

AU - Barra, S.

AU - Lamparelli, T.

AU - Gualandi, F.

AU - Mordini, N.

AU - Berisso, G.

AU - Bregante, S.

AU - Raiola, A. M.

AU - Van Lint, M. T.

AU - Frassoni, F.

PY - 2000

Y1 - 2000

N2 - One hundred and fifty acute myeloid leukaemia (AML) patients in first remission received an allogeneic bone marrow transplant (BMT), after conditioning with cyclophosphamide 120 mg/kg and total body irradiation (TBI) 3.3 Gy x 3 (total nominal dose 9.9). The received dose, as recorded by thermoluminescent dosimeters, ranged between 7.83 and 12.25 Gy. Patients who received TBI <9.9 Gy (n=34) had a significantly higher relapse rate when compared with patients receiving ≥9.9 Gy (n=116) (43% vs. 19%; P=0.002). Graft versus host disease (GvHD) prophylaxis consisted of cyclosporin A (CyA) with or without methotrexate (MTX). The dose of CyA was either 1 or 5 mg/kg/day i.v. from day -1 to + 20, then 10 mg/kg/day orally until day + 365. Patients receiving 5 mg/kg CyA (n=40) had a higher risk of relapse (49% vs. 15%; P=0.0001). Thus, low-dose TBI (

AB - One hundred and fifty acute myeloid leukaemia (AML) patients in first remission received an allogeneic bone marrow transplant (BMT), after conditioning with cyclophosphamide 120 mg/kg and total body irradiation (TBI) 3.3 Gy x 3 (total nominal dose 9.9). The received dose, as recorded by thermoluminescent dosimeters, ranged between 7.83 and 12.25 Gy. Patients who received TBI <9.9 Gy (n=34) had a significantly higher relapse rate when compared with patients receiving ≥9.9 Gy (n=116) (43% vs. 19%; P=0.002). Graft versus host disease (GvHD) prophylaxis consisted of cyclosporin A (CyA) with or without methotrexate (MTX). The dose of CyA was either 1 or 5 mg/kg/day i.v. from day -1 to + 20, then 10 mg/kg/day orally until day + 365. Patients receiving 5 mg/kg CyA (n=40) had a higher risk of relapse (49% vs. 15%; P=0.0001). Thus, low-dose TBI (

KW - Acute myeloid leukaemia

KW - Cyclosporin

KW - Graft vs. leukaemia

KW - Total body irradiation

UR - http://www.scopus.com/inward/record.url?scp=0033951358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033951358&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.01809.x

DO - 10.1046/j.1365-2141.2000.01809.x

M3 - Article

C2 - 10651732

AN - SCOPUS:0033951358

VL - 108

SP - 99

EP - 104

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -